The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer.
 
Simon Chowdhury
Stock and Other Ownership Interests - Telix Pharmaceuticals
Honoraria - Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Huma; Janssen-Cilag; Novartis; Pfizer; Remedy Bio; Telix Pharmaceuticals
Speakers' Bureau - Janssen-Cilag; Pfizer
 
Alan Bryce
Employment - City of Hope
Leadership - City of Hope
Honoraria - Astellas Pharma; Bayer; Bayer; Janssen; Janssen Oncology; Lantheus Medical Imaging; Lilly; MOMA Therapeutics; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Tolmar; Verity Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma
Travel, Accommodations, Expenses - Bayer; Pfizer; Pfizer (Inst); Tolmar
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer
 
M Isabel Saez
Consulting or Advisory Role - Merck
Speakers' Bureau - Astellas Oncology; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Ipsen
 
Charles Redfern
Stock and Other Ownership Interests - Pfizer
 
Ali Benjelloun
Stock and Other Ownership Interests - Crispr Therapeutics
Consulting or Advisory Role - Novartis
 
John Burke
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol Myers Squibb; CRISPR Therapeutics; Genentech/Roche; Genmab; Lilly; Novartis; Regeneron; Seagen
Travel, Accommodations, Expenses - Genentech/Roche
 
David Campbell
No Relationships to Disclose
 
Aude Flechon
Honoraria - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; NOVARTIS; PFIZER; Roche/Genentech; Sanofi/Aventis
Travel, Accommodations, Expenses - AAA HealthCare; Astellas Pharma; AstraZeneca; Bayer; BMS; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis
 
Zafar Malik
No Relationships to Disclose
 
Alison Reid
Honoraria - Astellas Oncology; Astellas Pharma (I); Janssen (I); Janssen Oncology; Novartis
Consulting or Advisory Role - Amgen (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blue Earth Therapeutics (I); Janssen Cilag (I); Merck (I); Merck Serono (I); Novartis (I); Pfizer (I); Veracyte (I)
Speakers' Bureau - Astellas Pharma (I); AstraZeneca (I); Janssen (I); Sandoz (I); Sanofi (I)
Research Funding - Astellas Pharma (I); Blue Earth Therapeutics (I); Janssen (I); Novartis (I); Veracyte (I)
Patents, Royalties, Other Intellectual Property - My spouse Prof Gert Attard has inventor rights for abiraterone acetate from The Institute of Cancer Research, London, UK. (I); Prof Gert Attard is listed as inventor on docetaxel predictive biomarker (Veracyte) (I); Prof Gert Attard is listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons) (I)
Travel, Accommodations, Expenses - Amgen (I); Astellas Pharma; Astellas Pharma (I); Bayer (I); Janssen (I); Janssen Oncology; Merck Serono (I); Pfizer (I)
 
Maria De Santis
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Thermosome
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; GlaxoSmithKline; Immunomedics/Gilead; Ipsen; Janssen; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Orion Health; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda; Thermosome
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Ipsen; Janssen; Merck Serono; Pfizer; Roche; Roche/Genentech; Sanofi
 
Julie Graff
Research Funding - Curium Pharma (Inst); Janssen Oncology (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
 
Vadim Koshkin
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol Myers Squibb Foundation; Janssen; Loxo; Merck; MSD; Pfizer; Roche/Genentech; Tempus
Research Funding - Curium Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pfizer/Astellas (Inst); Seagen (Inst); Taiho Oncology (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Alvaro Pinto
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis
Research Funding - Pfizer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Roche
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Eli Rosenbaum
Stock and Other Ownership Interests - Brainsway; CONergent
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; MSD; Teva
Speakers' Bureau - MSD
Research Funding - MSD
Travel, Accommodations, Expenses - Bayer
 
Christy Connor
Employment - pharma&
 
Merrissa Peynado
Employment - pharma&
 
Charles Ryan
Honoraria - Bayer; Janssen Oncology; Pfizer
Consulting or Advisory Role - ORIC Pharmaceuticals